Project 3:Isolation Chemistry of Filamentous Fungi and Biological Evaluation

$291,746P01FY2025CANIH

Ohio State University, Columbus OH

Investigators

Linked publications & trials

Paper 39479302 Paper 39396465 Paper 39280884 Paper 39164287 Paper 39095664 Paper 39079718 Paper 39039966 Paper 38964520 Paper 38947012 Paper 38629495 Paper 38341161 Paper 38328000 Paper 38237151 Paper 37731043 Paper 37643353 Paper 37579526 Paper 37449327 Paper 37387219 Paper 37319116 Paper 37216676 Paper 37194649 Paper 37155928 Paper 36914145 Paper 36884371 Paper 36879060 Paper 36498874 Paper 36431924 Paper 35963484 Paper 35963294 Paper 35834411 Paper 35427139 Paper 35421431 Paper 35351997 Paper 35268742 Paper 35213158 Paper 35137758 Paper 35100504 Paper 35099085 Paper 35077640 Paper 35020372 Paper 35017152 Paper 35013112 Paper 34848447 Paper 34421136 Paper 34314586 Paper 34208576 Paper 34191514 Paper 34157637 Paper 34155352 Paper 33927787 Paper 33859802 Paper 33784769 Paper 33769037 Paper 33764773 Paper 33662206 Paper 33588006 Paper 33495550 Paper 33484778 Paper 33454654 Paper 33289552 Paper 33288558 Paper 33124130 Paper 33099129 Paper 33006889 Paper 32829012 Paper 32817009 Paper 32786877 Paper 32502407 Paper 32437735 Paper 32407985 Paper 32235860 Paper 32106242 Paper 32096998 Paper 32096649 Paper 32083834 Paper 32052896 Paper 31953129 Paper 31931448 Paper 31909733 Paper 31898704 Paper 31848295 Paper 31823607 Paper 31823431 Paper 31769581 Paper 31633350 Paper 31621322 Paper 31598014 Paper 31465222 Paper 31120251 Paper 31112181 Paper 31032461 Paper 30837981 Paper 30830783 Paper 30783922 Paper 30658371 Paper 30633954 Paper 30620608 Paper 30613309 Paper 30294068 Paper 30259213

Abstract

PROJECT SUMMARY â PROJECT 3 There is a need for new anticancer drug leads, particularly for treating drug- resistant cancers. Fungi have been the source of many drug leads, with penicillin and the statins as two of the most prominent examples. It is hypothesized by Project 3 that fungi harbor anticancer drug leads, and we are addressing this via a team with expertise in mycology (Mycosynthetix, Inc./Pearce), natural products chemistry (UNCG/Oberlies), and chemical biology (Columbia/Stockwell). In the examination of thousands of fungal cultures from the Mycosythetix Inc.library, Project 3 has implemented biological and chemical protocols to prioritize our efforts. In doing so, we have identified hundreds of fungal metabolites with anticancer activity, approximately a third of which are new to the literature. Currently, we have prioritized three of these leads for further preclinical development, and our team is optimizing the biosynthesis of materials (targeting gram scale production) for pharmacology studies, PK/metabolism, and semi-synthetic optimization. One of these leads (verticillins) has shown a statistically significant response in an in vivo model of ovarian cancer. Another lead, eupenifeldin, showed a statistically significant response in an in vivo model of tumor resection in lung cancer. Both of these are undergoing further development, particularly lead optimization via semi-synthesis. A third lead is derived from fungal-fungal co-culture studies, which was an area of emphasis in the previous submission. An additional goal for generating new chemical diversity is the biosynthesis and/or semi-synthesis of non-natural natural products, via the incorporation of fluorine atoms into the privileged fungal-derived scaffolds. There are several areas documented in the proposal that demonstrate our teamâs ability to leverage ideas and collaborations to further advance promising fungal metabolites.

View original record on NIH RePORTER →